ArticleThe British journal of cardiology2025
A follow-up analysis of PCSK9 inhibition therapy in real-world practice: evaluating the efficacy of inclisiran.
Article in The British journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reduction in low-density lipoprotein-cholesterol (LDL-C) in patients with hypercholesterolaemia is associated with a lower risk of cardiovascular (CV) events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibiting therapy is approved by the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) for use in high-risk patients who are unable to achieve the LDL-C target levels, despite other maximum tolerated lipid-lowering therapies. Our prior publication analysed the records of patients in a large Scottish health board with familial hypercholesterolaemia and high CV risk and confirmed the real-world efficacy of PCSK9 inhibiting monoclonal antibodies (mAbs) in routine clinical care. In this follow-up study, we examined the comparative efficacy of inclisiran, a small-interfering ribonucleic acid (siRNA) therapeutic, in a similar patient cohort to provide real-world data that can guide clinicians in optimising lipid-lowering strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.